What are the precautions for taking Relugolix?

RelugolixIt is suitable for the treatment of adult patients with advanced prostate cancer. Relugolix, a combination product containing estradiol and norethindrone, is indicated for once-daily treatment to control heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

What are the precautions for taking Relugolix(Relugolix)?

1.PossibleQT/QTcinterval prolongation may occur. Androgen deprivation therapy (such asORGOVYX) can prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital longQT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider regular ECG and electrolyte monitoring.

2.Allergic reaction. It is contraindicated in patients who are severely allergicto Repaglifloxacin or to any of the product ingredientsRepagofloxacin. Post-marketing, allergic reactions, including pharyngeal edema and other severe cases of angioedema, have occurred in patients receiving regaglic. In the HERO study, angioedema (0.2%) was reported in patients receiving repaglifloz. Patients who experience any allergic symptoms are advised to temporarily discontinue use of Regolic and seek medical attention immediately. Discontinue Repagliflox due to severe allergic reaction and manage as clinically indicated.

3.Embryo-Fetal Toxicity. The safety and effectiveness of Repagliflozin in women have not been established. Based on the results of animal studies and its mechanism of action, taking Regolic by pregnant women may cause fetal harm and miscarriage. In an animal reproduction study, oral administration of Repagliflozin to pregnant rabbits during organogenesis resulted in maternally exposed fetal lethality, calculated as the area under the curve (AUC), of 0.3 for human exposure at the recommended dose of 120 mg daily.times. Men with female partners of childbearing potential are advised to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.

4.Laboratory testing

Treatment withrepagliflozinleads to suppression of the pituitary gonadal system. The results of diagnostic tests for pituitary gonadotropins and gonadal function performed during and after gonadal periods may be affected. The therapeutic efficacy of regaglic should be monitored by periodic measurement of serum concentrations of prostate-specific antigen (PSA). IfPSAis elevated, serum testosterone concentration should be measured. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0